GleamWall
中文EN

STLN Starling Oncology, Inc.

Services-Offices & Clinics of Doctors of Medicine · Nasdaq · SEC CIK 1799191 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY21.7%
TTM net income YoY5.6%
TTM EPS YoY16.9%
Revenue 3-yr CAGR25.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-8.9%
Net margin-14.4%
FCF margin-6.0%
EBITDA margin-7.4%

Returns

ROE-4,132.2%
ROA-38.7%
ROIC (approx.)-67.7%
Asset turnover2.69x

Leverage & solvency

Liabilities / assets107.5%
Debt / equity—
Current ratio1.68x
Interest coverage-3.90x

Cash quality & payout

Operating cash flow / net income0.36x
Accruals ratio-24.8%
Payout ratio—
Capex / revenue0.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$169.77M$161.28M$147.44M$141.96M$136.56M$119.80M$104.41M$100.27M
SG&A expense$32.13M$29.94M$28.21M$28.04M$25.25M$26.91M$25.38M$24.86M
Operating income-$2.98M-$4.62M-$6.51M-$6.91M-$8.05M-$11.21M-$9.91M-$11.93M
Interest expense$1.81M$1.86M$1.93M$1.92M$1.92M$1.87M$5.57M$1.17M
Pretax income-$15.75M-$9.79M-$2.49M-$7.51M-$16.50M-$17.14M-$19.59M-$13.18M
Income tax$0$0$0$0$0-$131,000$0$0
Net income-$15.75M-$9.79M-$2.49M-$7.51M-$16.50M-$17.01M-$19.59M-$13.18M
EBITDA-$1.46M-$2.78M-$4.90M-$5.28M-$6.33M-$9.41M-$8.13M-$10.22M
EPS (basic)-0.13-0.08-0.02—-0.14-0.15-0.21—
EPS (diluted)-0.13-0.08-0.02—-0.14-0.15-0.21—
Weighted avg. shares (diluted)104.73M103.03M101.80M—97.47M93.20M77.10M—
Balance sheet
Cash & equivalents$36.90M$41.09M$30.28M$33.56M$27.66M$30.29M$39.74M$49.67M
Short-term investments———————$0
Receivables$60.68M$66.35M$58.13M$59.00M$59.64M$55.66M$49.32M$48.34M
Inventory$36.63M$20.01M$24.29M$16.88M$18.88M$15.79M$12.31M$10.04M
Current assets$137.69M$128.99M$116.86M$112.75M$110.09M$104.79M$106.82M$112.42M
PP&E, net$10.59M$10.58M$10.70M$10.68M$10.71M$10.85M$11.12M$11.89M
Goodwill$7.23M$7.23M$7.23M$7.23M$7.23M$7.23M$7.23M$7.23M
Intangibles$8.87M$9.59M$10.30M$11.02M$11.73M$12.45M$14.04M$14.81M
Total assets$187.77M$178.23M$168.23M$164.66M$163.62M$159.80M$164.00M$172.72M
Current liabilities$123.70M$94.94M$79.35M$70.96M$65.58M$64.78M$59.54M$52.22M
Long-term debt$72.52M$79.87M$78.61M$77.40M$76.19M$75.02M$73.89M$93.13M
Total debt$72.52M$79.87M$78.61M$77.40M$76.19M$75.02M$73.89M$93.13M
Total liabilities$225.13M$203.15M$184.51M$180.38M$175.89M$168.78M$158.93M$169.13M
Shareholders' equity-$37.35M-$24.91M-$16.29M-$15.72M-$12.27M-$8.98M$5.07M$3.59M
Net debt$35.62M$38.77M$48.33M$43.84M$48.54M$44.73M$34.16M$43.46M
Shares outstanding101.99M100.47M99.97M98.86M97.57M93.28M88.93M75.74M
Cash flow statement
Operating cash flow$10.14M$11.94M-$2.21M$3.23M-$12.63M-$10.20M-$4.99M$4.00M
Capital expenditure$1.26M$908,000$1.04M$1.06M$604,000$1.21M$328,000$1.75M
Free cash flow$8.88M$11.03M-$3.26M$2.17M-$13.23M-$11.41M-$5.32M$2.25M
Investing cash flow-$1.26M-$908,000-$1.04M-$1.06M-$604,000-$1.21M-$202,000-$1.75M
Financing cash flow-$13.08M-$218,000-$28,000$3.73M$10.60M$1.96M-$4.74M-$164,000
Depreciation & amortization$1.52M$1.84M$1.62M$1.63M$1.72M$1.80M$1.78M$1.71M
Stock-based compensation$1.35M$1.07M$1.69M$1.32M$1.02M$752,000$1.46M$1.29M
Share buybacks———————$0

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.